JNJ

235.7

+0.74%↑

UNH

275.15

-1.93%↓

TMO

568.64

-0.99%↓

ABT

109.09

+0.67%↑

ISRG

475.33

-1.55%↓

JNJ

235.7

+0.74%↑

UNH

275.15

-1.93%↓

TMO

568.64

-0.99%↓

ABT

109.09

+0.67%↑

ISRG

475.33

-1.55%↓

JNJ

235.7

+0.74%↑

UNH

275.15

-1.93%↓

TMO

568.64

-0.99%↓

ABT

109.09

+0.67%↑

ISRG

475.33

-1.55%↓

JNJ

235.7

+0.74%↑

UNH

275.15

-1.93%↓

TMO

568.64

-0.99%↓

ABT

109.09

+0.67%↑

ISRG

475.33

-1.55%↓

JNJ

235.7

+0.74%↑

UNH

275.15

-1.93%↓

TMO

568.64

-0.99%↓

ABT

109.09

+0.67%↑

ISRG

475.33

-1.55%↓

Kodu・Aktsiate loetelu・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Avatud

3.67 -6.38

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.56

Max

3.9699999999999998

Põhinäitajad
By Trading Economics
Sissetulek	5.5M -28M
Müük	8.2M 13M
Kasumimarginaal	-208.694
Töötajad	172
EBITDA	8.7M -27M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+230% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-32M 222M
Eelmine avamishind	10.05
Eelmine sulgemishind	3.67

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

3.17 / 3.4644 Toetus ja vastupanu

Voyager Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. veebr 2026, 23:11 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3. veebr 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. veebr 2026, 23:50 UTC

Market Talk

Nikkei May Decline After Hitting All-Time High -- Market Talk

3. veebr 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

3. veebr 2026, 23:41 UTC

Omandamised, ülevõtmised, äriostud

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3. veebr 2026, 23:38 UTC

Tulu

AMD Sales Climb on Help From Data-Center Business -- Update

3. veebr 2026, 23:29 UTC

Omandamised, ülevõtmised, äriostud

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3. veebr 2026, 23:27 UTC

Omandamised, ülevõtmised, äriostud

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3. veebr 2026, 23:25 UTC

Omandamised, ülevõtmised, äriostud

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3. veebr 2026, 23:23 UTC

Omandamised, ülevõtmised, äriostud

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3. veebr 2026, 23:22 UTC

Omandamised, ülevõtmised, äriostud

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3. veebr 2026, 23:19 UTC

Market Talk

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3. veebr 2026, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

3. veebr 2026, 22:56 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3. veebr 2026, 22:40 UTC

Tulu

Amdocs Extends Collaboration With T-Mobile

3. veebr 2026, 22:39 UTC

Tulu

Amdocs 1Q Adj EPS $1.81

3. veebr 2026, 22:39 UTC

Tulu

Amdocs 1Q Rev $1.16B

3. veebr 2026, 22:39 UTC

Tulu

Amdocs 1Q EPS $1.45 >

3. veebr 2026, 22:38 UTC

Tulu

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3. veebr 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3. veebr 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3. veebr 2026, 22:14 UTC

Tulu

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3. veebr 2026, 22:13 UTC

Tulu

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3. veebr 2026, 22:12 UTC

Tulu

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3. veebr 2026, 22:10 UTC

Tulu

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3. veebr 2026, 22:10 UTC

Tulu

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3. veebr 2026, 22:10 UTC

Market Talk

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3. veebr 2026, 22:10 UTC

Tulu

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3. veebr 2026, 22:09 UTC

Tulu

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3. veebr 2026, 22:09 UTC

Tulu

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Võrdlus sarnastega

Hinnamuutus

Voyager Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

230% tõus

12 kuu keskmine prognoos

Keskmine 13.2 USD 230%

Kõrge 25 USD

Madal 8 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Voyager Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Voyager Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.17 / 3.4644Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.